Introduction to radiobiology of targeted radionuclide therapy

Jean-Pierre Pouget, Catherine Lozza, Emmanuel Deshayes, Vincent Boudousq, Isabelle Navarro-Teulon, Jean-Pierre Pouget, Catherine Lozza, Emmanuel Deshayes, Vincent Boudousq, Isabelle Navarro-Teulon

Abstract

During the last decades, new radionuclide-based targeted therapies have emerged as efficient tools for cancer treatment. Targeted radionuclide therapies (TRTs) are based on a multidisciplinary approach that involves the cooperation of specialists in several research fields. Among them, radiobiologists investigate the biological effects of ionizing radiation, specifically the molecular and cellular mechanisms involved in the radiation response. Most of the knowledge about radiation effects concerns external beam radiation therapy (EBRT) and radiobiology has then strongly contributed to the development of this therapeutic approach. Similarly, radiobiology and dosimetry are also assumed to be ways for improving TRT, in particular in the therapy of solid tumors, which are radioresistant. However, extrapolation of EBRT radiobiology to TRT is not straightforward. Indeed, the specific physical characteristics of TRT (heterogeneous and mixed irradiation, protracted exposure, and low absorbed dose rate) differ from those of conventional EBRT (homogeneous irradiation, short exposure, and high absorbed dose rate), and consequently the response of irradiated tissues might be different. Therefore, specific TRT radiobiology needs to be explored. Determining dose-effect correlation is also a prerequisite for rigorous preclinical radiobiology studies because dosimetry provides the necessary referential to all TRT situations. It is required too for developing patient-tailored TRT in the clinic in order to estimate the best dose for tumor control, while protecting the healthy tissues, thereby improving therapeutic efficacy. Finally, it will allow to determine the relative contribution of targeted effects (assumed to be dose-related) and non-targeted effects (assumed to be non-dose-related) of ionizing radiation. However, conversely to EBRT where it is routinely used, dosimetry is still challenging in TRT. Therefore, it constitutes with radiobiology, one of the main challenges of TRT in the future.

Keywords: bystander effects; radiobiology; radioimmunotherapy; targeted radionuclide therapy.

Figures

Figure 1
Figure 1
Targeted and non-targeted biological effects in conventional external beam radiotherapy. Targeted effects are caused by one or more particles traversing irradiated cells and can be divided in DNA and non-DNA-centered effects. Non-targeted effects describes the effects observed in cells that have not been directly traversed by particles but that are close to irradiated cells, as well as long-distance effects. DNA, mitochondria, and the cell membrane are the main sensitive targets of radiation. Following targeted and non-targeted effects, cells can survive (lesions are effectively repaired), they can die (lesions are not repaired) or they can be transformed. The dose–effect relationship of targeted effects is commonly fitted by linear or linear-quadratic models. A saturation of the response to non-targeted effects has been described. For more details, see the main text.
Figure 2
Figure 2
Targeted and non-targeted effects in targeted radionuclide therapy. Targeted effects are caused by one or more particles crossing irradiated cells and can be due to self-irradiation and cross-fire irradiation. Non-targeted effects include effects observed in cells close to irradiated cells and also long-distance effects. The nature of the dose–effect relationship resulting from targeted and non-targeted effects needs to be determined. For more details, see the main text.
Figure 3
Figure 3
Comparison of conventional external beam radiotherapy and targeted radionuclide therapy.

References

    1. Despeignes V. Observation concernant un cas de cancer de l’estomac traité par les rayons Roentge. In: Lyon Medical Lyon: Librairie Médicale de Louis Savy; (1896). p. 428–30; 503–6.
    1. Foray N. [Claudius Regaud (1870-1940): a pioneer of radiobiology and radiotherapy]. Cancer Radiother (2012) 16(4):315–21.10.1016/j.canrad.2012.05.006
    1. Wang CK. The progress of radiobiological models in modern radiotherapy with emphasis on the uncertainty issue. Mutat Res (2010) 704(1–3):175–81.10.1016/j.mrrev.2010.02.001
    1. Cadet J, Ravanat JL, TavernaPorro M, Menoni H, Angelov D. Oxidatively generated complex DNA damage: tandem and clustered lesions. Cancer Lett (2012) 327(1–2):5–15.10.1016/j.canlet.2012.04.005
    1. Riley PA. Free radicals in biology: oxidative stress and the effects of ionizing radiation. Int J Radiat Biol (1994) 65(1):27–33.10.1080/09553009414550041
    1. Hamada N, Maeda M, Otsuka K, Tomita M. Signaling pathways underpinning the manifestations of ionizing radiation-induced bystander effects. Curr Mol Pharmacol (2011) 4(2):79–95.10.2174/1874467211104020079
    1. Droge W. Free radicals in the physiological control of cell function. Physiol Rev (2002) 82(1):47–95.10.1152/physrev.00018.2001
    1. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 49(11):1603–16.10.1016/j.freeradbiomed.2010.09.006
    1. Hei TK, Zhou H, Chai Y, Ponnaiya B, Ivanov VN. Radiation induced non-targeted response: mechanism and potential clinical implications. Curr Mol Pharmacol (2011) 4(2):96–105.10.2174/1874467211104020096
    1. Hei TK, Zhou H, Ivanov VN, Hong M, Lieberman HB, Brenner DJ, et al. Mechanism of radiation-induced bystander effects: a unifying model. J Pharm Pharmacol (2008) 60(8):943–50.10.1211/jpp.60.8.0001
    1. Zhou H, Ivanov VN, Lien YC, Davidson M, Hei TK. Mitochondrial function and nuclear factor-kappaB-mediated signaling in radiation-induced bystander effects. Cancer Res (2008) 68(7):2233–40.10.1158/0008-5472.CAN-07-5278
    1. Matsumoto H, Tomita M, Otsuka K, Hatashita M, Hamada N. Nitric oxide is a key molecule serving as a bridge between radiation-induced bystander and adaptive responses. Curr Mol Pharmacol (2011) 4(2):126–34.10.2174/1874467211104020126
    1. Cadet J, Loft S, Olinski R, Evans MD, Bialkowski K, Richard Wagner J, et al. Biologically relevant oxidants and terminology, classification and nomenclature of oxidatively generated damage to nucleobases and 2-deoxyribose in nucleic acids. Free Radic Res (2012) 46(4):367–81.10.3109/10715762.2012.659248
    1. Pouget JP, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med (2001) 28(4):541–61.10.1007/s002590100484
    1. Goodhead DT. Initial events in the cellular effects of ionizing radiations: clustered damage in DNA. Int J Radiat Biol (1994) 65(1):7–17.10.1080/09553009414550021
    1. Georgakilas AG, O’Neill P, Stewart RD. Induction and repair of clustered DNA lesions: what do we know so far? Radiat Res (2013) 180(1):100–9.10.1667/RR3041.1
    1. Sutherland BM, Georgakilas AG, Bennett PV, Laval J, Sutherland JC. Quantifying clustered DNA damage induction and repair by gel electrophoresis, electronic imaging and number average length analysis. Mutat Res (2003) 531(1–2):93–107.10.1016/j.mrfmmm.2003.08.005
    1. Sage E, Harrison L. Clustered DNA lesion repair in eukaryotes: relevance to mutagenesis and cell survival. Mutat Res (2011) 711(1–2):123–33.10.1016/j.mrfmmm.2010.12.010
    1. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature (2000) 408(6811):433–9.10.1038/35044005
    1. Khanna KK, Lavin MF, Jackson SP, Mulhern TD. ATM, a central controller of cellular responses to DNA damage. Cell Death Differ (2001) 8(11):1052–65.10.1038/sj.cdd.4400874
    1. Khanna KK, Jackson SP. DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet (2001) 27(3):247–54.10.1038/85798
    1. Shiloh Y, Ziv Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat Rev Mol Cell Biol (2013) 14(4):197–21010.1038/nrm3546
    1. Maynard S, Schurman SH, Harboe C, de Souza-Pinto NC, Bohr VA. Base excision repair of oxidative DNA damage and association with cancer and aging. Carcinogenesis (2009) 30(1):2–10.10.1093/carcin/bgn250
    1. Svilar D, Goellner EM, Almeida KH, Sobol RW. Base excision repair and lesion-dependent subpathways for repair of oxidative DNA damage. Antioxid Redox Signal (2011) 14(12):2491–507.10.1089/ars.2010.3466
    1. Jeggo PA, Geuting V, Lobrich M. The role of homologous recombination in radiation-induced double-strand break repair. Radiother Oncol (2011) 101(1):7–12.10.1016/j.radonc.2011.06.019
    1. Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem (2010) 79:181–211.10.1146/annurev.biochem.052308.093131
    1. Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med (1956) 103(5):653–6610.1084/jem.103.5.653
    1. Vogin G, Foray N. The law of Bergonie and Tribondeau: a nice formula for a first approximation. Int J Radiat Biol (2013) 89(1):2–8.10.3109/09553002.2012.717732
    1. Lambert WC, Gagna CE, Lambert MW. Xeroderma pigmentosum: its overlap with trichothiodystrophy, Cockayne syndrome and other progeroid syndromes. Adv Exp Med Biol (2008) 637:128–3710.1007/978-0-387-09599-8_14
    1. Jorgensen TJ, Shiloh Y. The ATM gene and the radiobiology of ataxia- telangiectasia. Int J Radiat Biol (1996) 69(5):527–3710.1080/095530096145535
    1. Zhao S, Weng YC, Yuan SS, Lin YT, Hsu HC, Lin SC, et al. Functional link between ataxia-telangiectasia and Nijmegen breakage syndrome gene products. Nature (2000) 405(6785):473–7.10.1038/35013083
    1. Barendsen GW, Beusker TL, Vergroesen AJ, Budke L. Effects of different radiations on human cells in tissue culture. II. Biological experiments. Radiat Res (1960) 13:841–910.2307/3570858
    1. Barendsen GW, Walter HM, Fowler JF, Bewley DK. Effects of different ionizing radiations on human cells in tissue culture. III. Experiments with cyclotron-accelerated alpha-particles and deuterons. Radiat Res (1963) 18:106–1910.2307/3571430
    1. Barendsen GW. Dose-survival curves of human cells in tissue culture irradiated with alpha-, beta-, 20-kV. x- and 200-kV. x-radiation. Nature (1962) 193:1153–510.1038/1931153a0
    1. Barendsen GW. Modification of radiation damage by fractionation of the dose, anoxia, and chemical protectors in relation to let. Ann N Y Acad Sci (1964) 114:96–11410.1111/j.1749-6632.1964.tb53565.x
    1. Barendsen GW, Walter HM. Effects of different ionizing radiations on human cells in tissue culture. iv. Modification of radiation damage. Radiat Res (1964) 21:314–2910.2307/3571569
    1. Deschavanne PJ, Malaise EP. The relevance of alpha/beta ratios determined in vitro for human cell lines to the understanding of in vivo values. Int J Radiat Biol (1989) 56(5):539–4210.1080/09553008914551701
    1. Thames HD, Bentzen SM, Turesson I, Overgaard M, van den Bogaert W. Fractionation parameters for human tissues and tumors. Int J Radiat Biol (1989) 56(5):701–10.10.1080/09553008914551931
    1. De Ridder M, Jiang H, Van Esch G, Law K, Monsaert C, Van den Berge DL, et al. IFN-gamma+ CD8+ T lymphocytes: possible link between immune and radiation responses in tumor-relevant hypoxia. Int J Radiat Oncol Biol Phys (2008) 71(3):647–51.10.1016/j.ijrobp.2008.03.014
    1. Morgan GW, Breit SN. Radiation and the lung: a reevaluation of the mechanisms mediating pulmonary injury. Int J Radiat Oncol Biol Phys (1995) 31(2):361–9.10.1016/0360-3016(94)00477-3
    1. Calveley VL, Khan MA, Yeung IW, Vandyk J, Hill RP. Partial volume rat lung irradiation: temporal fluctuations of in-field and out-of-field DNA damage and inflammatory cytokines following irradiation. Int J Radiat Biol (2005) 81(12):887–99.10.1080/09553000600568002
    1. Shao C, Folkard M, Michael BD, Prise KM. Bystander signaling between glioma cells and fibroblasts targeted with counted particles. Int J Cancer (2005) 116(1):45–51.10.1002/ijc.21003
    1. Murphy JB, Liu JH, Sturm E. Studies on X-ray effects: Ix. The action of serum from X-rayed animals on lymphoid cells in vitro. J Exp Med (1922) 35(3):373–84.10.1084/jem.35.3.373
    1. Mole RH. Whole body irradiation; radiobiology or medicine? Br J Radiol (1953) 26(305):234–4110.1259/0007-1285-26-305-234
    1. Hollowell JG, Jr, Littlefield LG. Chromosome damage induced by plasma of x-rayed patients: an indirect effect of x-ray. Proc Soc Exp Biol Med (1968) 129(1):240–410.3181/00379727-129-33295
    1. Emerit I, Levy A, Cernjavski L, Arutyunyan R, Oganesyan N, Pogosian A, et al. Transferable clastogenic activity in plasma from persons exposed as salvage personnel of the Chernobyl reactor. J Cancer Res Clin Oncol (1994) 120(9):558–61.10.1007/BF01221035
    1. Nagasawa H, Little JB. Induction of sister chromatid exchanges by extremely low doses of alpha-particles. Cancer Res (1992) 52(22):6394–6.
    1. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys (2004) 58(3):862–70.10.1016/j.ijrobp.2003.09.012
    1. Demaria S, Formenti SC. Role of T lymphocytes in tumor response to radiotherapy. Front Oncol (2012) 2:95.10.3389/fonc.2012.00095
    1. Prise KM, O’Sullivan JM. Radiation-induced bystander signalling in cancer therapy. Nat Rev Cancer (2009) 9(5):351–60.10.1038/nrc2603
    1. Lee Y, Auh SL, Wang Y, Burnette B, Wang Y, Meng Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood (2009) 114(3):589–95.10.1182/blood-2009-02-206870
    1. Havaki S, Kotsinas A, Chronopoulos E, Kletsas D, Georgakilas A, Gorgoulis VG. The role of oxidative DNA damage in radiation induced bystander effect. Cancer Lett (2015) 356(1):43–51.10.1016/j.canlet.2014.01.023
    1. Andarawewa KL, Paupert J, Pal A, Barcellos-Hoff MH. New rationales for using TGFbeta inhibitors in radiotherapy. Int J Radiat Biol (2007) 83(11–12):803–11.10.1080/09553000701711063
    1. Lee H, Herrmann A, Deng JH, Kujawski M, Niu G, Li Z, et al. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell (2009) 15(4):283–93.10.1016/j.ccr.2009.02.015
    1. Grivennikov SI, Karin M. Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev (2010) 21(1):11–9.10.1016/j.cytogfr.2009.11.005
    1. Burdak-Rothkamm S, Rothkamm K, Prise KM. ATM acts downstream of ATR in the DNA damage response signaling of bystander cells. Cancer Res (2008) 68(17):7059–65.10.1158/0008-5472.CAN-08-0545
    1. Alper T. Effects on irradiated micro-organisms of growth in the presence of acriflavine. Nature (1963) 200:534–610.1038/200534a0
    1. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer (2003) 3(4):276–8510.1038/nrc1046
    1. Corre I, Niaudet C, Paris F. Plasma membrane signaling induced by ionizing radiation. Mutat Res (2010) 704(1–3):61–7.10.1016/j.mrrev.2010.01.014
    1. Kolesnick RN, Haimovitz-Friedman A, Fuks Z. The sphingomyelin signal transduction pathway mediates apoptosis for tumor necrosis factor, Fas, and ionizing radiation. Biochem Cell Biol (1994) 72(11–12):471–4.10.1139/o94-063
    1. Haimovitz-Friedman A, Kan CC, Ehleiter D, Persaud RS, McLoughlin M, Fuks Z, et al. Ionizing radiation acts on cellular membranes to generate ceramide and initiate apoptosis. J Exp Med (1994) 180(2):525–35.10.1084/jem.180.2.525
    1. Haimovitz-Friedman A, Balaban N, McLoughlin M, Ehleiter D, Michaeli J, Vlodavsky I, et al. Protein kinase C mediates basic fibroblast growth factor protection of endothelial cells against radiation-induced apoptosis. Cancer Res (1994) 54(10):2591–7.
    1. Poyton RO, Ball KA, Castello PR. Mitochondrial generation of free radicals and hypoxic signaling. Trends Endocrinol Metab (2009) 20(7):332–40.10.1016/j.tem.2009.04.001
    1. Murphy JE, Nugent S, Seymour C, Mothersill C. Mitochondrial DNA point mutations and a novel deletion induced by direct low-LET radiation and by medium from irradiated cells. Mutat Res (2005) 585(1–2):127–36.10.1016/j.mrgentox.2005.04.011
    1. Druzhyna NM, Wilson GL, LeDoux SP. Mitochondrial DNA repair in aging and disease. Mech Ageing Dev (2008) 129(7–8):383–9010.1016/j.mad.2008.03.002
    1. Graziewicz MA, Day BJ, Copeland WC. The mitochondrial DNA polymerase as a target of oxidative damage. Nucleic Acids Res (2002) 30(13):2817–24.10.1093/nar/gkf392
    1. Prithivirajsingh S, Story MD, Bergh SA, Geara FB, Ang KK, Ismail SM, et al. Accumulation of the common mitochondrial DNA deletion induced by ionizing radiation. FEBS Lett (2004) 571(1–3):227–32.10.1016/j.febslet.2004.06.078
    1. Bodet-Milin C, Ferrer L, Pallardy A, Eugène T, Rauscher A, Faivre-Chauvet A, et al. Radioimmunotherapy of B-cell non-Hodgkin’s lymphoma. Front Oncol (2013) 3:177.10.3389/fonc.2013.00177
    1. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med (2005) 352(5):441–9.10.1056/NEJMoa041511
    1. Pouget JP, Navarro-Teulon I, Bardiès M, Chouin N, Cartron G, Pèlegrin A, et al. Clinical radioimmunotherapy – the role of radiobiology. Nat Rev Clin Oncol (2011) 8(12):720–34.10.1038/nrclinonc.2011.160
    1. DeNardo SJ, Denardo GL. Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys (2006) 66(2 Suppl):S89–95.10.1016/j.ijrobp.2006.03.066
    1. Navarro-Teulon I, Lozza C, Pèlegrin A, Vivès E, Pouget JP. General overview of radioimmunotherapy of solid tumors. Immunotherapy (2013) 5(5):467–87.10.2217/imt.13.34
    1. Sharkey RM, Goldenberg DM. Cancer radioimmunotherapy. Immunotherapy (2011) 3(3):349–70.10.2217/imt.10.114
    1. Chouin N, Bernardeau K, Bardiès M, Faivre-Chauvet A, Bourgeois M, Apostolidis C, et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. II. Application of the microdosimetric model to experimental results. Radiat Res (2009) 171(6):664–73.10.1667/RR1536.1
    1. Chouin N, Bernardeau K, Davodeau F, Chérel M, Faivre-Chauvet A, Bourgeois M, et al. Evidence of extranuclear cell sensitivity to alpha-particle radiation using a microdosimetric model. I. Presentation and validation of a microdosimetric model. Radiat Res (2009) 171(6):657–63.10.1667/RR1371.1
    1. Pouget JP, Santoro L, Raymond L, Chouin N, Bardiès M, Bascoul-Mollevi C, et al. Cell membrane is a more sensitive target than cytoplasm to dense ionization produced by auger electrons. Radiat Res (2008) 170(2):192–200.10.1667/RR1359.1
    1. Freudenberg R, Runge R, Maucksch U, Berger V, Kotzerke J. On the dose calculation at the cellular level and its implications for the RBE of (99m)Tc and (1)(2)(3)I. Med Phys (2014) 41(6):062503.10.1118/1.4876296
    1. Piron B, Paillas S, Boudousq V, Pèlegrin A, Bascoul-Mollevi C, Chouin N, et al. DNA damage-centered signaling pathways are effectively activated during low dose-rate auger radioimmunotherapy. Nucl Med Biol (2014) 41(Suppl):e75–83.10.1016/j.nucmedbio.2014.01.012
    1. Bolch WE, Eckerman KF, Sgouros G, Thomas SR. MIRD pamphlet No. 21: a generalized schema for radiopharmaceutical dosimetry – standardization of nomenclature. J Nucl Med (2009) 50(3):477–84.10.2967/jnumed.108.056036
    1. Neti PV, Howell RW. Log normal distribution of cellular uptake of radioactivity: implications for biologic responses to radiopharmaceuticals. J Nucl Med (2006) 47(6):1049–58.
    1. Back T, Jacobsson L. The alpha-camera: a quantitative digital autoradiography technique using a charge-coupled device for ex vivo high-resolution bioimaging of alpha-particles. J Nucl Med (2010) 51(10):1616–23.10.2967/jnumed.110.077578
    1. Ritt P, Vija H, Hornegger J, Kuwert T. Absolute quantification in SPECT. Eur J Nucl Med Mol Imaging (2011) 38(Suppl 1):S69–77.10.1007/s00259-011-1770-8
    1. Tornai MP, Jaszczak RJ, Turkington TG, Coleman RE, et al. Small-animal PET: advent of a new era of PET research. J Nucl Med (1999) 40(7):1176–9.
    1. Lassmann M, Chiesa C, Flux G, Bardiès M, EANM Dosimetry Committee . EANM dosimetry committee guidance document: good practice of clinical dosimetry reporting. Eur J Nucl Med Mol Imaging (2011) 38(1):192–200.10.1007/s00259-010-1549-3
    1. Stabin MG, Peterson TE, Holburn GE, Emmons MA, et al. Voxel-based mouse and rat models for internal dose calculations. J Nucl Med (2006) 47(4):655–9.
    1. Bitar A, Lisbona A, Thedrez P, Sai Maurel C, Le Forestier D, Barbet J, et al. A voxel-based mouse for internal dose calculations using Monte Carlo simulations (MCNP). Phys Med Biol (2007) 52(4):1013–25.10.1088/0031-9155/52/4/010
    1. Goddu SM, Howell RW, Bouchet LG, Bolch WE, Rao DV. MIRD Cellular S Values: Self-Absorbed Dose Per Unit Cumulated Activity for Selected Radionuclides and Monoenergetic Electron and Alpha Particle Emitters Incorporated into Different Cell Compartments. Reston, VA: Society of Nuclear Medicine; (1997).
    1. Boutaleb S, Pouget JP, Hindorf C, Pelegrin A, Barbet J, Kotzki PO, et al. Impact of mouse model on pre-clinical dosimetry in targeted radionuclide therapy. Proc IEEE (2009) 87:2076–8510.1109/JPROC.2009.2026921
    1. Flux GD, Haq M, Chittenden SJ, Buckley S, Hindorf C, Newbold K, et al. A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer. Eur J Nucl Med Mol Imaging (2010) 37(2):270–5.10.1007/s00259-009-1261-3
    1. Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H, et al. Tumor-absorbed dose predicts progression-free survival following 131I-tositumomab radioimmunotherapy. J Nucl Med (2014) 55(7):1047–53.10.2967/jnumed.113.136044
    1. Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD, et al. 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med (2010) 51(7):1155–62.10.2967/jnumed.110.075176
    1. Strigari L, Konijnenberg M, Chiesa C, Bardies M, Du Y, Gleisner KS, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. Eur J Nucl Med Mol Imaging (2014) 41:1976–88.10.1007/s00259-014-2824-5
    1. Sgouros G, Squeri S, Ballangrud AM, Kolbert KS, Teitcher JB, Panageas KS, et al. Patient-specific, 3-dimensional dosimetry in non-Hodgkin’s lymphoma patients treated with 131I-anti-B1 antibody: assessment of tumor dose-response. J Nucl Med (2003) 44(2):260–8.
    1. Wessels BW, Konijnenberg MW, Dale RG, Breitz HB, Cremonesi M, Meredith RF, et al. MIRD pamphlet No. 20: the effect of model assumptions on kidney dosimetry and response – implications for radionuclide therapy. J Nucl Med (2008) 49(11):1884–99.10.2967/jnumed.108.053173
    1. Wessels BW, Vessella RL, Palme DF, II, Berkopec JM, Smith GK, Bradley EW. Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys (1989) 17(6):1257–63.10.1016/0360-3016(89)90534-8
    1. Ning S, Knox SJ. G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat Res (1999) 151(6):659–69.10.2307/3580204
    1. Sgouros G, Knox SJ, Joiner MC, Morgan WF, Kassis AI. MIRD continuing education: bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med (2007) 48(10):1683–91.10.2967/jnumed.105.028183
    1. Knox SJ, Goris ML, Wessels BW. Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol (1992) 23(2):111–7.10.1016/0167-8140(92)90342-R
    1. Knox SJ, Sutherland W, Goris ML. Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Radiat Res (1993) 135(1):24–31.10.2307/3578392
    1. Fowler JF. Radiobiological aspects of low dose rates in radioimmunotherapy. Int J Radiat Oncol Biol Phys (1990) 18(5):1261–9.10.1016/0360-3016(90)90467-X
    1. Murtha AD. Radiobiology of low-dose-rate radiation relevant to radioimmunotherapy. Cancer Biother Radiopharm (2000) 15(1):7–14.10.1089/cbr.2000.15.7
    1. Murtha AD. Review of low-dose-rate radiobiology for clinicians. Semin Radiat Oncol (2000) 10(2):133–8.10.1016/S1053-4296(00)80050-8
    1. Brady D, O’Sullivan JM, Prise KM. What is the role of the bystander response in radionuclide therapies? Front Oncol (2013) 3:215.10.3389/fonc.2013.00215
    1. Prise KM, Schettino G, Folkard M, Held KD. New insights on cell death from radiation exposure. Lancet Oncol (2005) 6(7):520–8.10.1016/S1470-2045(05)70246-1
    1. Boyd M, Ross SC, Dorrens J, Fullerton NE, Tan KW, Zalutsky MR, et al. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides. J Nucl Med (2006) 47(6):1007–15.
    1. Paillas S, Boudousq V, Piron B, Kersual N, Bardiès M, Chouin N, et al. Apoptosis and p53 are not involved in the anti-tumor efficacy of (1)(2)(5)I-labeled monoclonal antibodies targeting the cell membrane. Nucl Med Biol (2013) 40(4):471–80.10.1016/j.nucmedbio.2013.02.001
    1. Boyd M, Sorensen A, McCluskey AG, Mairs RJ. Radiation quality-dependent bystander effects elicited by targeted radionuclides. J Pharm Pharmacol (2008) 60(8):951–8.10.1211/jpp.60.8.0002
    1. Bishayee A, Rao DV, Howell RW. Evidence for pronounced bystander effects caused by nonuniform distributions of radioactivity using a novel three-dimensional tissue culture model. Radiat Res (1999) 152(1):88–9710.2307/3580054

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe